Novartis agreed to buy Excellergy, adding anti-IgE asset Exl-111 to its pipeline as the pharma continues expanding immunology capabilities through early-stage acquisitions. Exl-111 is currently in Phase I testing and is positioned for immune and inflammatory indications such as food allergy and chronic urticaria. In parallel, Otsuka is taking steps to bring a clinical-stage PTSD program forward through its planned acquisition of Transcend. The two transactions highlight a narrow but consistent buying pattern: immunology and CNS assets where mechanism-based platforms may translate quickly into clinical differentiation. Investors are likely to focus on whether Exl-111 can show early safety and target engagement that supports downstream Phase 2 efficacy readouts, especially in an allergy market crowded with biologics.